Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 1999

View Archived Issues

BioHy study initiated for treatment of osteoarthritis of the knee

UroGenesys announces U.S. patent for PSA promoter sequences

Beta LT demonstrates positive results in initial human trials

Licensing opportunity from NIH: thymosin beta4 as a wound-healing agent

PDL granted new European patent covering humanized monoclonal antibodies

Company Profile: Diamyd Medical

SkyePharma acquires nanoparticle technology

Biomira revises collaboration with Chiron for Theratope vaccine

GPC and Novalon collaboration for discovery of broad-spectrum antibiotics

Celera Genomics and Gemini Research establish research collaboration

Novel antimycotic NND-502 assessed in systemic and lung infection models

Merck successfully completes tender offer for outstanding shares of Sibia Neurosciences

Isis reacquires full rights to ISIS-2302 and negotiates with commercialization partners

Company Profile: Biofrontera

Orally active nucleoside prodrugs for HBV and HIV infections designed at Medivir

German collaboration yields new inhibitors of human tryptase

Oxazolidinones with broad-spectrum activity claimed by Bayer

Preparation and use of live HIV vaccine reported by Research Development Foundation

N-(Phenylalkyl)cinnamides as structurally novel NR2B-selective NMDA receptor antagonists

Dr. Reddy performs SAR studies in the area of antidiabetic/hypolipidemic thiazolidinediones

Schering-Plough and British Biotech to develop MMPIs for treatment of cancer

Potent, selective human beta3-adrenoceptor antagonists discovered at Merck & Co.

Cambridge Antibody Technology reports positive initial results from CAT-152 trial

Cyclic peptide represents new lead for tumor-targeting anticancer therapies

Landmark HOPE study results presented at European cardiology meeting last week

Evidence of clinical efficacy and safety of UT-15 in primary pulmonary hypertension

ACE inhibitors, AII antagonists may have antiatherogenic effects according to studies in SHR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.